299 related articles for article (PubMed ID: 25936472)
1. Immunohistochemical characterization of the mTOR pathway in stage-I non-small-cell lung carcinoma.
Shin E; Choi CM; Kim HR; Jang SJ; Park YS
Lung Cancer; 2015 Jul; 89(1):13-8. PubMed ID: 25936472
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.
Tang JM; He QY; Guo RX; Chang XJ
Lung Cancer; 2006 Feb; 51(2):181-91. PubMed ID: 16324768
[TBL] [Abstract][Full Text] [Related]
3. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
4. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
5. Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma.
Kim HS; Kim GY; Lim SJ; Kim YW
Pathobiology; 2012; 79(2):84-93. PubMed ID: 22286903
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer.
Yoshizawa A; Fukuoka J; Shimizu S; Shilo K; Franks TJ; Hewitt SM; Fujii T; Cordon-Cardo C; Jen J; Travis WD
Clin Cancer Res; 2010 Jan; 16(1):240-8. PubMed ID: 20008839
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of p-Akt, p-mTOR and p-eIF4E proteins associates with metastasis and unfavorable prognosis in non-small cell lung cancer.
Lu J; Zang H; Zheng H; Zhan Y; Yang Y; Zhang Y; Liu S; Feng J; Wen Q; Long M; Fan S
PLoS One; 2020; 15(2):e0227768. PubMed ID: 32023262
[TBL] [Abstract][Full Text] [Related]
8. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.
Dobashi Y; Suzuki S; Kimura M; Matsubara H; Tsubochi H; Imoto I; Ooi A
Hum Pathol; 2011 Feb; 42(2):214-26. PubMed ID: 21040950
[TBL] [Abstract][Full Text] [Related]
9. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA
Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983
[TBL] [Abstract][Full Text] [Related]
10. Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.
Stojsic J; Stankovic T; Stojkovic S; Milinkovic V; Dinic J; Milosevic Z; Milovanovic Z; Tanic N; Bankovic J
Exp Mol Pathol; 2015 Feb; 98(1):27-32. PubMed ID: 25449334
[TBL] [Abstract][Full Text] [Related]
11. PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer.
Lim WT; Zhang WH; Miller CR; Watters JW; Gao F; Viswanathan A; Govindan R; McLeod HL
Oncol Rep; 2007 Apr; 17(4):853-7. PubMed ID: 17342327
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of the mammalian target of rapamycin pathway in penile squamous cell carcinomas: a tissue microarray study of 112 cases.
Chaux A; Munari E; Cubilla AL; Hicks J; Lecksell K; Burnett AL; Netto GJ
Histopathology; 2014 May; 64(6):863-71. PubMed ID: 24279699
[TBL] [Abstract][Full Text] [Related]
13. High levels of phosphatase and tensin homolog expression are associated with tumor progression, tumor recurrence, and systemic metastases in pT1 urothelial carcinoma of the bladder: a tissue microarray study of 156 patients treated by transurethral resection.
Chaux A; Compérat E; Varinot J; Hicks J; Lecksell K; Solus J; Netto GJ
Urology; 2013 Jan; 81(1):116-22. PubMed ID: 23273076
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study.
Gately K; Al-Alao B; T Dhillon ; Mauri F; Cuffe S; Seckl M; O'Byrne K
Lung Cancer; 2012 Feb; 75(2):217-22. PubMed ID: 21802763
[TBL] [Abstract][Full Text] [Related]
15. The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas.
Setsu N; Yamamoto H; Kohashi K; Endo M; Matsuda S; Yokoyama R; Nishiyama K; Iwamoto Y; Dobashi Y; Oda Y
Cancer; 2012 Mar; 118(6):1637-48. PubMed ID: 21837670
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer.
Dhillon T; Mauri FA; Bellezza G; Cagini L; Barbareschi M; North BV; Seckl MJ
J Thorac Oncol; 2010 Mar; 5(3):314-9. PubMed ID: 20093977
[TBL] [Abstract][Full Text] [Related]
17. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
Nishikawa M; Miyake H; Harada K; Fujisawa M
Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
19. Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma.
Liu D; Huang Y; Chen B; Zeng J; Guo N; Zhang S; Liu L; Xu H; Mo X; Li W
Cancer; 2011 Aug; 117(16):3763-73. PubMed ID: 21387259
[TBL] [Abstract][Full Text] [Related]
20. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS
J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
